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Abstract
Background: To assess the impact of disease activity on health-related quality of life (HRQoL) in systemic lupus
erythematosus (SLE).
Methods: Cross-sectional study of patients included in the Swiss SLE Cohort Study between April 2007 and June
2014. HRQoL outcomes were based on the Medical Outcome Study Short Form 36 (SF-36). Disease activity was
assessed by the SLE Disease Activity Index score with the Safety of Estrogens in SLE National Assessment
modification (SELENA-SLEDAI) and by the physican’s global assessment (PGA).
Results: Of the 252 patients included, 207 (82%) were women. Median [interquartile range (IQR)] age was 43 [32–57]
years. SLE was active in 125 patients (49.6%). Median [IQR] mental component summary (MCS) in active vs inactive SLE
was 40.0 [30.2–51.0] compared to 47.3 [39.2–52.8] (p < 0.01) and median [IQR] physical component summary (PCS) 43.7
[37.0–52.8] compared to 49.1 [38.4–55.6], respectively (p < 0.05). Increase in SELENA-SLEDAI or increase in PGA were
negatively correlated with PCS and/or MCS. After adjusting for gender, age and disease duration, disease activity
impacted on both PCS and MCS and all subscales except general health. Active lupus nephritis and musculoskeletal
involvement were associated with physical limitations and emotional problems, increased bodily pain and poor social
functioning. Low complement and/or presence of anti-dsDNA antibodies were associated with increased fatigue and
reduced mental health.
Conclusions: In patients with SLE, HRQoL is reduced in those with active disease. Impact of disease activity on HRQoL
dimensions depends on SELENA-SLEDAI system components.
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Background
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease that mainly affects women. This multifac-
torial disease arises in genetically susceptible individuals
upon activation of the innate and adaptive immune system
through internal and environmental factors [1]. Clinical
presentation is diverse and may include joint, skin, kidney,
neurological or hematological involvement [2]. Sustained
inflammation in tissues may lead to organ dysfunction
and failure. Fatigue and pain are also prominent com-
plaints in SLE patients [3, 4]. SLE activity and damage in
addition to fatigue and pain impact on patients quality of
life (QoL) [5, 6]. Thus, treatment in SLE should not
only aim at decreasing disease activity and damage
accrual but also at improving health-related quality of
life (HRQOL) [7].
Both lupus-specific QoL questionnaires and the generic
Medical Outcomes Study 36-Item Short Form Health
Survey (SF-36) have been used to assess HRQOL in SLE
[8]. Most SLE studies have used the SF-36, showing that
this tool reliably assess HRQOL in this disease [5, 9–11].
SF-36 outcomes have been used as endpoints for treat-
ment efficacy or as prognostic marker [7, 10, 12]. The in-
fluence of disease activity on HRQOL is still debated,
possibly because only a few studies have examined
disease-related organ involvement in relationship with
HRQOL [13–19]. Herein we aimed at assessing baseline
HRQOL in a cohort of adult SLE patients [2, 20] and to
correlate SF36 scores with global disease activity. In order
to further emphasize the possible influence of disease
activity on SLE, we assessed the impact of organ involve-
ment on HRQOL.
Methods
Patients
Cross-sectional data were collected on patients sequen-
tially included in the Swiss SLE Cohort Study (SSCS)
between April 2007 and June 2014. Inclusion criteria were:
age ≥ 18 years, diagnosis SLE according to the updated
ACR classification criteria [21, 22] or the SLICC 2012
criteria [23], completed SF-36 and corresponding data on
disease activity, manifestations and treatment. The cohort
study was approved by the ethics review boards of all
participating institutions and all patients gave written
informed consent. Patients included originated from
Clinical Immunology, Internal Medicine, Nephrology, and
Rheumatology tertiary care centers located both in the
French and German-speaking regions of Switzerland.
Data collection
Data on patient’s age, sex, ethnicity and family history of
SLE, dates of first lupus manifestation and diagnosis,
clinical and biological characteristics at baseline, disease
activity, laboratory parameters, treatment modalities and
co-morbidity were collected. HRQoL was assessed by
the SF-36 Version 1 [24, 25]. This tool comprises 8
dimension-scales: physical function (PF), role limitations
due to physical problems (role physical, RP), bodily pain
(BP), general health (GH), vitality (VT), social function
(SF), role limitations due to emotional problems (role
emotional, RE), and mental health (MH). Each scale
ranges from 0 (lowest possible score) to 100 (highest
possible score). These 8 dimensions can be summarized
into two global scores, the physical component summary
(PCS) and the mental component summary (MCS).
Expected SF-36 outcomes for an age- and sex-matched
population were generated using an algorithm based on
the results of a survey conducted on 1200 adults in
Western Switzerland [26]. Disease activity was assessed
independently of the SF-36 on the same day, using the
Systemic Lupus Erythematosus Disease Activity Index
(SLEDAI) score with the Safety of Estrogens in Lupus
Erythematosus National Assessment (SELENA) modifi-
cation [27]. Patients were classified in 2 groups accord-
ing to their SELENA-SLEDAI: inactive SLE (SLEDAI < 4)
and active SLE (SLEDAI ≥ 4). Disease activity was also
assessed by the Physician’s Global Assessment (PGA)
score with a 4–point-Likert-scale, ranging from 0
(inactive disease) to 3 (very active disease). Medication
was detailed for disease-modifying drugs (DMARD’s)
taken, which were classified in three groups: systemic
glucocorticosteroids (GC), anti-malarials (AM) and
immunosuppressive agents (IS). All parameters reflected
the 4-week period preceding completion of the SF-36 [28].
Primary outcomes
Primary outcomes were the differences in the eight SF36
dimension scales at baseline in patients with active and
inactive disease.
Statistical analysis
Quantitative variables were expressed as the median ±
interquartile range (IQR) and non-parametric statistics
were used to analyze the data. P-values < 0.05 (two-sided)
were considered significant. A linear regression model was
used for multivariate analysis, with SF-36 dimension as
dependent variables and age, sex, disease duration and
SELENA-SLEDAI system components as independent
variables. The purpose of this analysis was to identify
which of the SELENA-SLEDAI system component were
most strongly associated with differences in SF-36 dimen-
sions. Statistical analysis was performed using GraphPad
Prism version 6.00 (GraphPad Software, La Jolla, CA), and
SPSS Version 22 (IBM Corp Armonk, NY). Spydergrams
were generated using Excel Version 14 (Microsoft,
Redmond, Washington).
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Results
Two hundred and fifty-two patients met the inclusion
criteria. Patients’ baseline characteristics are shown in
Table 1. Approximately half of the patients had inactive
disease (Table 1). Those with active disease defined as
SELENA-SLEDAI ≥ 4 accordingly had a higher PGA
score. They were more often smokers and positive for
anti-Sm antibodies. They also had higher ESR values,
lower hemoglobin and serum albumin levels and received
more often GC and higher average daily prednisone doses
(Table 1). HRQoL outcomes in SLE were significantly
reduced compared to what is expected in the age- and
Table 1 Characteristics of 252 patients with sytemic lupus erythematosus with inactive and active disease at inclusion
Characteristics All (N = 252) Inactivea (N = 127) Activea (N = 125) p-value
Sex, women/men (%) 207/45 (82/18) 104/23 (82/18) 103/22 (82/18) 1.00
Age, median [IQR], years 43 [32–57] 45 [32–59] 42 [32–55] 0.23
Body mass index, median [IQR], kg/m2 24.1 [21.2–27.4] 24.4 [22.0–28.5] 24.0 [20.9–26.7] 0.07
Smoking, no (%) 46 (18) 15 (12) 31 (25) <0.01
Disease duration, median [IQR], years 6.2 [2.6–14.3] 6.0 [2.9–12.8] 6.6 [2.3–15.1] 0.45
ACR criteria
Malar rash, no (%) 92 (37) 42 (33) 50 (40) 0.30
Discoid rash, no (%) 46 (18) 28 (22) 18 (14) 0.14
Photosensitivity, no (%) 121 (48) 58 (46) 63 (50) 0.53
Nasopharyngeal ulcers, no (%) 70 (28) 35 (28) 35 (28) 1.00
Arthritis, no (%) 173 (69) 83 (65) 90 (72) 0.28
Pleuritis, no (%) 58 (23) 26 (21) 32 (26) 0.45
Pericarditis, no (%) 44 (18) 23 (18) 21 (17) 0.87
Renal disorder, no (%) 90 (36) 39 (31) 51 (41) 0.12
Seizures, no (%) 12 (5) 4 (3) 8 (6) 0.25
Psychosis, no (%) 13 (5) 6 (5) 7 (6) 0.78
Hematologic disorder, no (%) 155 (62) 73 (58) 82 (66) 0.20
Antinuclear antibodies positive, no (%) 246 (98) 125 (98) 121 (97) 0.44
Anti-Sm antibody positive, no (%) 38 (15) 13 (10) 25 (20) 0.035
Anti-dsDNA antibodies positive, no (%) 150 (60) 68 (54) 82 (66) 0.055
Anti-phospholipid antibodies positive, no (%) 108 (43) 55 (43) 53 (42) 0.90
Laboratory values
Haemoglobin, median [IQR], g/L 130 [117–137] 131 [122–138] 128 [113–135] 0.011
Leukocytes, median [IQR], G/L 5.9 [4.5–7.7] 5.6 [4.3–7.5] 6.2 [4.6–8.35] 0.12
Platelets, median [IQR], G/L 238 [189–294] 240 [189–285] 236 [185–303] 0.97
Plasma creatinin, median [IQR], μmol/L 70 [61–87] 70 [61–86] 70 [61–92] 0.64
Serum albumin, median [IQR], g/L 39.2 [36.6–42.0] 40.1 [38.8–42.7] 38 [35.0–40.3] <0.0001
Erythrocyte sedimentation rate, median [IQR], mm/1st hour 12 [6–29] 10 [5–26] 14 [7–34] 0.013
Disease activity and damage
Physician global assesment, median [IQR] 0 [0–1] 0 [0–1] 1 [0–1.25] <0.0001
SELENA-SLEDAI, median [IQR] 3 [0.25–8] 1 [0–2] 8 [4–12] <0.0001
Treatment
Oral glucocorticosteroids, no (%) 141 (56.0) 55 (43.3) 85 (68) <0.0001
Daily prednisone equivalent, median [IQR], mg 7.5 [5–12] 5 [5–7.5] 9 [5–20] <0.0001
Antimalarials, no (%) 178 (71) 91 (71) 87 (70) 0.68
Immunosuppressants, no (%) 120 (48) 55 (43) 65 (52) 0.21
SD Standard deviation, IQR Interquartile range, NS non significant, SELENA-SLEDAI Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score with the
Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA), SDI Systemic Lupus International Collaborating Clinics/American College of Rheumatology
Damage Index
aInactive disease at baseline was defined by a SELENA-SLEDAI < 4 and active disease by a SELENA-SLEDAI ≥ 4
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sex-matched Swiss general population: Median [IQR] PCS
in SLE was 46.0 [37.9–54.4] in contrast to expected 52.0
[46.8–57.2], and median [IQR] MCS in SLE was 44.5
[33.6–52.1], in contrast to expected 50.3 [48.7–51.9] (both
p < 0.001). Except for RE, all other SF-36 dimensions were
significantly lower in SLE compared to the expected re-
sults in the general population (Fig. 1). Within the SLE
group and among general characteristics, only age and
body mass index appeared to be negatively correlated with
HRQoL outcomes, whereas gender, disease duration and
smoking status were not (Table 2). Advanced age nega-
tively impacted mainly on PF and BP, with a median scale
of 78.6 and 66.4 in individuals younger than 35 years and
62.3 and 54.5 in those older than 55 years (p < 0.001 and
p = 0.002), respectively. Although to a lesser extent than
age, an increase in body mass index also negatively corre-
lated with HRQoL, in particular with PF and BP (Table 2).
Disease activity had a negative influence on all dimen-
sions of HRQOL, except on GH perception (Fig. 2;
Table 2). Accordingly, patients with active SLE had sig-
nificantly lower MCS (40.0 [30.2–51.0]) and lower PCS
(43.7 [37.0–52.8]), compared to patients with inactive
disease (MCS 47.3 [39.2–52.8], p < 0.01), and PCS 49.1
[38.4–55.6], p < 0.05). The association between active
SLE and poor HRQoL was confirmed when relying on
PGA for disease activity (Fig. 2; Table 2). However, the
correlation between BP and disease activity was stronger
when assessed by PGA, compared to SELENA-SLEDAI.
One the other hand, SELENA-SLEDAI correlated more
closely with the RE dimension than PGA. SELENA-
SLEDAI correlated more strongly with MCS and PGA
with PCS (Table 2).
Among biological activity parameters, an elevated
erythrocyte sedimentation rate negatively correlated with
most SF-36 dimensions, while hemoglobin and serum
albumin levels correlated positively with some (Table 2).
Regarding SLE treatment, GC and IS were associ-
ated with active disease, while AM were not (Table 1).
Use of GC at the time of visit was associated with a
decrease in particular in the RP dimension, with a
mean score of 43.8 compared to 66.4 in patients not
taking GC (p < 0.001).
After adjusting for gender, age and disease duration,
disease activity measured by SELENA-SLEDAI impacted
on both summary component scales of the SF-36 and all
dimension, except GH (Table 3). The effects of the nine
SELENA-SLEDAI organ systems on HRQoL are shown
in Table 4. (and detailed in Additional file 1: Table S1).
Activity in the musculoskeletal, renal and immuno-
logical components significantly affected one or more
SF-36 dimensions, while there was no significant
impact of constitutional signs, serositis, active cutane-
ous, vascular, and central nervous or hematologic
involvement. Musculoskeletal SLE activity defined as
arthritis or myositis was strongly associated with BP,
but also negatively affected RP, RE and SF, as well as
MH. Renal SLE activity defined by hematuria, pyuria,
new or increasing proteinuria and/or presence of
urinary casts was negatively associated with RE and
RP subscales, and to a lesser extent with BP, VT and
SF. Immunologic activity defined by low complement
levels and/or presence of anti-dsDNA antibodies had
a negative impact on VT and MH. Interestingly, the
influence of musculoskeletal and renal activity on
HRQoL did not depend on age, whereas the impact
of vascular involvement became non-significant and
that of immunologic activity substantial once adjusted
for age, sex and disease duration.
Fig. 1 Spydergrams of the eight baseline SF-36 dimensions in 252 patients included in the Swiss Systemic Lupus Erythematosus Cohort Study
compared to the expected values in an age- and sex-matched sample of the Swiss general population. PF physical function, RP role physical,
BP bodily pain, GH general health, VT vitality, SF social function, RE role emotional, MH mental health. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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Table 2 Spearman’s correlations between baseline characteristics and the eight dimensions and component summaries of the SF-36
in 252 patients with systemic lupus erythematosus
Disease characteristics PF RP BP GH VT SF RE MH PCS MCS
Age at assessment −0.27**** −0.08 −0.18** −0.05 −0.01 0.02 −0.07 0.15* −0.24*** 0.06
Body mass index −0.25*** −0.12 −0,16* −0.07 −0.11 −0.13 −0.15* 0.01 −0.18** −0.05
Disease duration 0.14* 0.13 0.02 0.03 0.11 0.06 0.03 0.14* 0.12 0.02
SELENA-SLEDAI −0.07 −0.27** −0.22** −0.09 −0.15* −0.14* −0.27** −0.16* −0.14* −0.21***
PGA −0.17** −0.23*** −0.32**** −0.08 −0.13* −0.13* −0.19** −0.16* −0.21*** −0.14*
ESR −0.26*** −0.24*** −0.23*** −0.11 −0.13 −0.15* −0.21** −0.14* −0.23*** −0.14*
Haemoglobin 0.16* 0.19** 0.07 0.04 0.05 0.09 0.14** 0.01 0.14* 0.06
Serum albumin level 0.06 0.16* 0.12 0.01 −0.01 0.14 0.11 −0.04 0.12 0.02
Daily prednisone equivalent −0.03 −0.16 −0.17 0.09 −0.01 −0.18* −0.10 −0.09 −0.08 −0.10
ESR Erythrocyte sedimentation rate, PGA Physician’s global assessment, SELENA-SLEDAI Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score with
the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA), SDI Systemic Lupus International Collaborating Clinics/American College of
Rheumatology Damage Index, PF physical function, RP role physical, BP bodily pain, GH general health, VT vitality, SF social function, RE role emotional,
MH mental health, PCS Physical Component Summary, MCS Mental Component Summary
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Fig. 2 Spydergrams of the eight baseline SF-36 dimensions in 252 patients included in the Swiss Systemic Lupus Erythematosus Cohort Study according
to disease activity measures including SELENA-SLEDAI (a) and PGA (b) scores. SELENA-SLEDAI = Systemic Lupus Erythematosus Disease Activity Index
(SLEDAI) score with the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA); PGA= Physican’s global assessment; PF = physical
function; RP = role physical; BP = bodily pain; GH=general health; VT = vitality; SF = social function; RE = role emotional; MH=mental health. *p< 0.05,
**p< 0.01, ***p< 0.001, ****p<0.001
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Discussion
This study shows a reduction in most HRQoL outcomes
in patients with active SLE, when assessed by the SF-36.
Global disease activity is a strong predictor of HRQoL,
even when adjusted for other factors such as age, sex
and disease duration. While nearly all dimension of the
SF-36 appear reduced in SLE in contrast to what is
expected in an age- and gender-matched general popula-
tion, with the SLE group active disease defined by a
SELENA-SLEDAI ≥ 4 has a dramatic effect on the
dimensions that reflect the patient’s role limitations. The
relation between global SLE activity and HRQoL was
assessed by other cross-sectional as well as longitudinal
studies, with conflicting results [13–19]. For instance,
two studies by Hanly and Gladman relying on the SF-20
[13, 14] did not find a correlation between disease activ-
ity and HRQOL. On the other hand, Stoll et al. using
the SF-36 reported a significant association between dis-
ease activity assessed by the British Isles Lupus Activity
Group System (BILAG) and HRQoL [15].
In this work, we aimed at further deciphering which di-
mensions were affected by global disease activity and
SELENA-SLEDAI system components. Our results show
that the SELENA-SLEDAI score with a 4-week window
Table 3 Linear regression analysis on health-related quality of life outcomes in 252 patients with systemic lupus erythematosus in
regard with disease activity age, sex and disease duration
Outcomes Predictors
SELENA-SLEDAI, unadjusted (N = 252) SLEDAI, adjusted for age, sex and disease duration (N = 225)
Difference in SF-36 score
for a 1-point increase in
SELENA-SLEDAI
95%-C.I. p Difference in SF-36 score
for a 1-point increase in
SELENA-SLEDAI
95%-C.I. p
Physical function −0.57 (−1.05, −0.10) 0.019 −0.66 (−1.12, −0.19) 0.006
Role physical −1.86 (−2.63, −1.09) <0.001 −1.85 (−2.63, −1.07) <0.001
Bodily pain −1.16 (−1.68, −0.64) <0.001 −1.27 (−1.79, −0.74) <0.001
General health −0.31 (−0.70, 0.08) 0.12 −0.27 (−0.67, 0.13) 0.19
Vitality −0.48 (−0.86, −0.10) 0.014 −0.46 (−0.86, −0.07) 0.022
Social function −0.72 (−1.19, −0.25) <0.001 −0.71 (−1.20, −0.22) 0.005
Role emotional −1.92 (−2.73, −1.11) <0.01 −1.86 (−2.70, −1.01) <0.001
Mental health −0.48 (−0.84, −0.13) 0.008 −0.46 (−0.81, −0.11) 0.011
Mental component summary −0.31 (−0.50, −0.12) 0.002 −0.34 (−0.53, −0.15) <0.001
Physical component summary −0.36 (−0.57, −0.15) 0.001 −0.33 (−0.55, −0.11) 0.003
SELENA-SLEDAI Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score with the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)
Table 4 Impact of disease activity by organ systems assessed through the SELENA-SLEDAI on health-related quality of life outcomes
in 252 patients with systemic lupus erythematosus
Predictors Outcomes
Unadjusted (N = 252) PF RP BP GH VT SF RE MH
SLEDAI organ group B p B p B p B p B p B p B P B p
Musculoskeletal −6.75 0.11 −18.45 0.008 −21.89 <0.001 −4.84 0.15 −4.01 0.23 −8.80 0.032 −20.27 0.005 −6.85 0.027
Vascular −27.12 0.019 −39.45 0.040 −12.96 0.32 −7.51 0.43 −7.13 0.44 −4.79 0.68 −32.58 0.11 1.47 0.86
Renal −5.35 0.16 −20.68 0.001 −10.07 0.02 −1.87 0.54 −6.88 0.022 −9.99 0.007 −24.41 <0.001 −3.00 0.29
Immunologic 1.88 0.56 −4.96 0.36 2.24 0.54 0.04 0.99 −4.67 0.070 −2.08 0.51 −8.06 0.15 −4.14 0.084
Adjusteda (N = 225) PF RP BP GH VT SF RE MH
SLEDAI organ group B P B P B p B P B P B P B P B P
Musculoskeletal −7.40 0.069 −16.29 0.020 −21.85 <0.001 −3.77 0.27 −3.40 0.32 −8.39 0.050 −17.60 0.019 −6.35 0.038
Vascular −15.29 0.22 −34.71 0.10 −6.98 0.63 −4.56 0.66 −6.24 0.54 −1.76 0.89 −32.29 0.16 −1.75 0.85
Renal −6.41 0.09 −21.99 0.001 −11.57 0.01 −1.52 0.63 −7.26 0.022 −9.89 0.012 −25.47 <0.001 −2.43 0.40
Immunologic −1.83 0.59 −6.60 0.26 −0.68 0.86 −0.97 0.73 −6.09 0.030 −3.34 0.35 −8.06 0.19 −5.14 0.041
B Regression coefficient: Difference in the SF-36 subscale in patients with organ dysfunction, PF physical function, RP role physical, BP bodily pain, GH general
health, VT vitality, SF social function, RE role emotional, MH mental health, SELENA-SLEDAI Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score with
the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)
aAdjusted for sex, age, disease duration
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negatively affects every dimension assessed by the SF-36,
with the exception of the perceived general health. Disease
activity assessed by the physician with a 4-Likert-scale ran-
ging from inactive to very active disease had a similar im-
pact on HRQoL outcomes, with the difference that it was
more closely associated with bodily pain and the physical
component summary. SELENA-SLEDAI on the other
hand was more closely associated with the mental compo-
nent summary. Overall, global disease activity predomin-
antly affected role physical and role emotional functioning
as well as bodily pain. We used the SELENA-SLEDAI
organ system classification [27] to differentiate which type
of SLE activity impacted most on HRQoL. Active muscu-
loskeletal and renal lupus had a negative influence on
most SF-36 dimensions. The impacts of SLE musculoskel-
etal and renal involvements on HRQoL have been previ-
ously reported: In a retrospective study of 303 patients,
musculoskeletal flares in the preceding year were inde-
pendently associated with impairment of most of the sub-
scales of the SF-36, except role limitation due to physical
problems and mental health [29]. This is in contrast with
our findings, where active musculoskeletal involvement
also impaired physical role and mental health, but had no
significant effect on physical functioning, general health
and vitality. This contrast could be explained by the
4-week window used in our study to assess disease activ-
ity, the definition of musculoskeletal involvement based
on the SELENA-SLEDAI [30] and by socio-cultural differ-
ences in the populations studied. We also found that ac-
tivity assessed by PGA was more closely correlated with
bodily pain than the SELENA-SLEDAI, which emphasizes
the importance of the physician’s impression in globally
assessing SLE patients. In accordance with previous stud-
ies our results underline that controlling musculoskeletal
activity is of major importance when aiming at improving
HRQoL in SLE.
Only few studies have addressed the impact of lupus
nephritis on HRQoL. Vu et al. showed in 1999 that
patients with lupus nephritis who progress to end stage
renal disease have reduced physical functioning and gen-
eral health subscales, while mental health appear to im-
prove [31]. Strand et al. reported an improvement of
HRQoL in SLE patients treated with sodium abetimus.
Strikingly, they also found that the role emotional dimen-
sion was significantly reduced in lupus nephritis and that
after treatment of renal flares this dimension was also the
one to improve the most [32]. More recently, Hanly et al.
evaluated the consequence of lupus nephritis on HRQoL.
Despite no significant difference in HRQoL outcomes be-
tween patients with lupus nephritis and those with non-
renal SLE, they showed that patients with advanced renal
failure had lower SF-36 subscales (mainly role physical)
and summary component scales [33, 34]. Our work shows
that among different organs systems assessed for SLE
activity, active lupus nephritis had the most pronounced
effect on role physical and role emotional functioning.
Thus, when assessing response to treatment in patients
with lupus nephritis, not only disease activity should be
measured but also HRQoL outcomes. Interestingly we
found that complement consumption and/or presence of
anti-dsDNA antibodies were associated with a decrease in
mental health and vitality subscales. The increase in
fatigue in immunologically active disease also recalls the
results of the BLISS studies, where patients with immuno-
logically active SLE had a better response to belimumab in
terms of HRQoL [7]. Altogether these observations may
strengthen the impression that immunologic disturbances
in SLE are directly responsible for patients’ fatigue and
mental alteration. One could hypothesize that pathogenic
auto-antibodies, and in particular those targeting dsDNA
may exert an effect on the central nervous system [35].
We did not find a correlation between active central ner-
vous system involvement and HRQoL, but this analysis
was limited by the fact that only few patients had overt
neurologic involvement. Hanly et al. also extensively stud-
ied the impact of psychiatric and neurological SLE symp-
toms on HRQoL. They found that mood disorders and
headaches were associated with lower mental and physical
component summaries, whereas seizures did not impact
on HRQoL outcomes. They however found no correlation
between the SLEDAI-2 K score or lupus auto-antibodies
and HRQoL [11, 36, 37].
Our study has some limitations. Indeed, most patients
in our study population had long-standing SLE. Still our
results regarding disease activity are similar to those re-
ported in a recent inception cohort study, where patients
with active SLE had poorer HRQOL outcomes [5]. Also,
while up to 75% of our patients had been diagnosed with
SLE two years or more prior to assessment, HRQoL out-
comes in the above mentioned longitudinal study did not
change significantly from two years after diagnosis on-
wards [5]. Thus, we believe that our results regarding dis-
ease activity are valid despite the cross-sectional design.
We were not able to assess factors such as educational
level and presence of fibromyalgia, which are known to
negatively impact on HRQoL [18, 38]. Lastly, our study
was not able to address the chronicity of SLE, which will
need repeated assessment of both disease activity and
HRQOL over a longer period.
Conclusions
In conclusion, our study confirms a low HRQoL in a large
cohort of Swiss SLE patients. Disease activity assessed by
SELENA-SLEDAI, PGA and ESR all negatively correlate
with most HRQoL outcomes. HrQoL was decreased in
those with active musculoskeletal and renal involvement
and in the presence of classical markers of biological
activity.
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